Editors' Insights: Rare variant of #Becker muscular #dystrophy: The role of a #cardiomyopathy mindset in an advanced-age patient. https://t.co/MxAPYVvZ6q #PolishHeartJournal #CardioTwitter #HeartNews #Cardiology @NadelMaciej @umedlodz

Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association https://t.co/HKdjKAhB6P

Interatrial septum thickness ≥ 5.2 mm in subcostal view identifies ATTRwt-CA with 80 % sensitivity & 78.6 % specificity #CardioTwitter https://t.co/FEo6RJHRYq

SCOUT-HCM Trial design mava in adolescents with oHCM https://t.co/86LMikZHSj #CardioTwitter

Good news for upcoming MyPEAK-1 trial: in 100 pts with MYBPC3tv, 84% had anti-AAV9 NAb ≤1:40, indicating broad eligibility for TN-201 - another step towards gene therapy in HCM 🧬 https://t.co/CPXdzIZmGK

New episode of Myocardial News is out : genotype vs phenotype in DCM, new data fromATTRibute-CM • debate on RV muscle bundle measurements • sleep apnea in HCM, myosin activation, a case of hydroxychloroquine cardiomyopathy + 2 new HFA statements. https://t.co/bUiA1O13Ad

V International Workshop on #Cardiomyopathies Kick-off with #HCM genetics 🔑 Messages @jpocardio @jodieingles27 Do NOT stop at gene negative without considering: 🧬 NGS panel? Genocopies included? 🧬Proband's pretest probability? 🧬Intermediate effect variants? #HCM future 🔜

🆕chapter in #amyloidosis: timely diagnosis, specific therapies & improved survival for our patients! We now know the earlier we treat, the better! But,what if we target the disease before its onset?🤯 🧵Introducing the ACT-EARLY trial

🧬💖You are still on time to send an abstract or register with an early fee to the ESC CardioGenomics conference in Lisbon! Share you science with top researchers from across Europe 🇪🇺 🗓️Abstracts deadline: 16 September 25 🗓️Early fee registration: 13 October 25 See you there!

🚨 Excited to share our latest work! “Impact of Genetic Testing & Family Screening in Hereditary Transthyretin Amyloidosis” 🧬❤️ Cascade genetic screening in ATTRv families 👨‍👩‍👧 enables earlier diagnosis, treatment & counselling. Here’s what we found 👇🧵

How can AI transform HCM care? 🔍 Diagnosis 📊 Risk stratification 🧬 Personalized medicine 👥 Digital-twin platforms (SMASH-HCM) Read our new review in EHJ–Digital Health: https://t.co/DI6iuJa8B0

Myocardial News Special Episode for the ESC 2025 congress is now available! #CardioTwitter #ESC2025

MAPLE HCM presented by @dr_pavia #ESC2025 #cardiotwitter

1/2: Coming out Oct 2! The 3rd Ed of Hypertrophic Cardiomyopathy w/ expanded content, board style Q&A & 4 section editors: @MasriAhmadMD @tikuowens @MartinMaronMD @mmartinezheart Amazon Link: https://t.co/Ab4sdNHyG2 or buy from @springerpub for 20% discount (next post)

MAGNITUDE phase III trial: Nex-Z vs placebo in ATTR-CM, will increase sample size to 1200 patients #CardioTwitter

🔴 Artificial intelligence-enabled electrocardiography & echocardiography to track preclinical progression of TTR amyloid cardiomyopathy @ESC_Journals #CardioEd #Cardiology #Amyloidosis @ekoikonomou #AI

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy @danmassera et al. JAHA https://t.co/nNSKBWLNp8 For more, visit Myocardial News: https://t.co/50VuAs9hP1

This month in Myocardial News: In a real-world study, patients with obstructive HCM refractory to advanced therapy (myectomy, ASA, disopyramide, pacing) showed similar clinical benefit and safety with mavacamten as those treated de novo. #HCM #cardiotwitter

🚨Mark your calendars! Join us Sept 12 at NYU for our Hypertrophic Cardiomyopathy Symposium — cutting-edge science, expert panels, and the latest in diagnosis & treatment. Don’t miss it! #NYUCardiology Agenda https://t.co/6lduasWiwO https://t.co/OcV0zy2esQ

Safety and Feasibility of Transcatheter Edge-to-Edge Repair of Mitral Regurgitation in Cardiac Amyloidosis by: Julia Vogel, @luedike, @LarsMichelMD et al. https://t.co/zdz2zWGHFg For more, visit Myocardial News: